

microRNA-605 inhibits the oncogenicity of non-small-cell lung cancer by directly targeting Forkhead Box PI

This article was published in the following Dove Press journal: OncoTargets and Therapy

Wei Zhou¹ Ruichao Li²

¹Department of Pneumology, Liyuan Hospital of Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei 430077, People's Republic of China; ²Department of Gerontology, Tongji Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei 430030, People's Republic of China

Correspondes Vei Znou Department to neumology, Liyuan Hospital of Tong, Tedical College of Huazhong University of Science and Technology, No.39 Yanhe Road, Wuhan, Hubei 430077, People's Republic of China Tel +861 860 715 2789 Email weizhou_tj@163.com

Ruichao Li

Department of Gerontology, Tongji Hospital Tongji Medical College Huazhong University of Science and Technology, No.1095, Jiefang Ave, Wuhan, Hubei 430030, People's Republic of China Tel +861 388 617 1191 Email ruichao_li@yeah.net **Background and aims:** microRNA-605 (miR-605) is dysragulated by antiple cancers and plays crucial roles in regulating cancer progretion. However, little is known about the expression pattern and detailed roles of mic-605 con-small-ord lung cancer (NSCLC). Thus, in this study, we evaluated miRe 15 expression in MCLC along with its clinical significance. More importantly, the chailed les and the anderlying molecular mechanisms of miR-605 in NSCLC were explored.

Material and methods: Of initiative reverse transcription polymerase chain reaction (RT-qPCR) was employed to detect miR-605 excression in NSCLC tissues and cell lines. A series of experiments were performed to determine the effects of miR-605 upregulation on NSCLC cell proliferation, apoptosis, migrature and invesion in vitro and tumor growth in vivo. In addition, the downstream is the experiments of miR-605 action in NSCLC cells were explored.

Results: Decrease expression miR-605 was frequently detected in NSCLC tissues and cell line. Low expression of miR-605 was significantly correlated with the tumor size, TNM stage, and do and monostasis in NSCLC patients. Exogenous miR-605 expression inhibited redifferation increases apoptosis, and inhibited metastasis of NSCLC cells in vitro. Add low ray, miR-605 overexpression hindered the growth of NSCLC cells in vivo. Further are, Forkhead Box P1 (FOXP1) was identified as a direct target gene of miR-605 in NSCLC cells. Moreover, FOXP1 was highly expressed in NSCLC cells and showed an averse correlation with miR-605 expression levels. Besides, silencing of FOXP1 simulated roll similar to miR-605 upregulation in NSCLC cells. FOXP1 reintroduction partially abolished the anticancer effects of miR-605 in NSCLC cells.

Conclusion: Our results revealed that miR-605 inhibited the oncogenicity of NSCLC cells in vitro and in vivo by directly targeting FOXP1, suggesting the importance of the miR-605/FOXP1 pathway in the malignant development of NSCLC.

Keywords: non-small-cell lung cancer, microRNA-605, proliferation, apoptosis, metastasis, Forkhead Box P1

Introduction

Lung cancer is one of the most frequently diagnosed human malignancies and the leading cause of cancer-related deaths globally. Approximately 1.825 million newly diagnosed cases and 1.59 million mortalities caused by lung cancer are predicted every year all over the world. Lung cancer could be divided into two main subtypes, non-small-cell lung cancer (NSCLC) and small-cell lung cancer, which account for 85% and 15% of all lung cancer cases, respectively. Currently, the primary therapy for

NSCLC is surgical resection, followed by chemotherapy, radiotherapy, and other anti-tumor therapy. With the notable development of therapeutic strategies in recent years, the treatment outcomes of patients with all stages of NSCLC have improved to a certain extent; however, the curative effects of cancer therapy remain unsatisfactory. Therefore, an in-depth elucidation of the mechanisms underlying the occurrence and development of NSCLC is imperative to the development of novel and effective therapeutic targets for patients with this fatal disease.

microRNAs (miRNAs) are a group of non-coding, short RNA molecules made up of 17–24 nucleotides.⁶ miRNAs function as endogenous RNA silencing molecules through complementary binding to the 3'untranslated regions (3'-UTRs) of their target genes, resulting in mRNA degradation or promoting gene silencing by suppressing translation.⁷ Emerging studies have demonstrated that the expression of miRNA molecules is abnormal in most human malignancies and they play crucial roles in tumorigenesis and tumor development.⁸⁻¹⁰ A variety of miRNAs have been reported to be aberrantly expressed in NSCLC.11 For example, miR-212,12 miR-409,¹³ and miR-4317¹⁴ are downregulated in NSCLC, whereas miR-21,15 miR-105,16 and miR-42117 expressed at high levels. Dysregulation of miRNA is clo sely related with the progression and develope NSCLC through participating in the regulation of m tiple biological behaviors, thus acting either oncog tumor suppressors. 18 Hence, identifying new NAs and investigating their roles in NSC progress. might facilitate the identification of need the peutic targets for treating patients with NSCV in the future

miR-605 is dysregulated in multiple cancers and play crucial roles in regulating cancer progression. ^{19–21} However, little is known bout the expression pattern and detailed coes of miR-60 air ASCLC. Thus, in this study, we dected the expression of miR-605 in NSCLC and investigated that croises and the underlying molecular mechanisms of miR-605 in NSCLC were elucidated.

Materials and methods

Tissue specimens

Paired NSCLC tissues and adjacent normal lung tissues were collected from 45 patients who underwent surgical resection at Liyuan Hospital of Tongji Medical College of Huazhong University of Science and Technology between October 2015 and November 2017. None of the patients had received chemotherapy, radiotherapy or other anti-tumor therapy before surgical resection. Tissue specimens were resected, frozen in liquid nitrogen, and then stored at -80 °C until RNA extraction. This research was approved by the Ethics Committee of Liyuan Hospital of Tongji Medical College of Huazhong University of Science and Technology, and was performed in accordance with the Declaration of Helsinki. In addition, written informed consent was obtained from all participants prior to their enrollment this study.

Cell lines and culture conditions

A non-tumorigenic bronch's epithen in cell the BEAS-2B and four human NS LC cell thes (N. C., SK-MES-1, H522, and H1299) were such sed from Shanghai Institute of Biochemistry and Cell Enlogy (Stanghai, China). The cells were mannely cultured. Dulbecco's modified Eagle's medium (D. EM) containing 10% fetal bovine serum (D. EM) containing 10% fetal bovine serum (D. EM) (both from Sibco, Thermo Fisher Scientific, Inc. (Waltham, MA, USA) and 1% v/v penicillinstre lomycin (Silona-Aldrich, St. Louis, MO, USA). All cells are culticated in a humidified incubator at 37 °C applied with 5% CO₂.

Cell transfection experiments

iR-605 mimics and negative control miRNA mimics (miR-NC) were ordered from Guangzhou RiboBio Co., Ltd (Guangzhou, China). Small interfering RNA (siRNA) targeting FOXP1 expression (si-FOXP1) and negative control siRNA (si-NC) were chemically synthesized by GenePharma Co. Ltd. (Shanghai, China). FOXP1 overexpression vector pCMV-FOXP1 and pCMV empty plasmid was generated by GeneCopoeia Co. Ltd. (Guangzhou, China). For transfection, cells were plated into 6-well plates with a density of 5×10⁵ cells per well and allowed to adhere overnight. LipofectamineTM 2000 (Invitrogen, Thermo Fisher Scientific, Inc., Waltham, MA, USA) was used for cell transfection, according to the manufacturer's instructions. Cells were collected at different times after transfection and used for further analysis.

RNA extraction and quantitative reverse transcription polymerase chain reaction (RT-qPCR)

Total RNA was isolated from tissue specimens or cultured cells using TRIzol reagent (Thermo Fisher Scientific, Inc.,

Waltham, MA, USA) following the manufacturer's protocol. The concentration of total RNA was determined using NanoDrop ND-1000 (Thermo Fisher Scientific, Inc., Waltham, MA, USA). For quantification of miR-605 expression, total RNA was reverse transcribed to cDNA using a miScript Reverse Transcription kit (Qiagen GmbH, Hilden, Germany). Next, quantitative PCR (qPCR) was performed using a miScript SYBR Green PCR kit (Qiagen GmbH, Hilden, Germany). To analyze FOXP1 mRNA expression, total RNA was reverse transcribed into cDNA using a PrimeScript RT Reagent Kit (TaKaRa, Tokyo, Japan). The PCR amplification for quantifying the expression of FOXP1 mRNA was carried out using a SYBR Premix Ex Taq (TaKaRa, Tokyo, Japan). U6 small nuclear RNA and GAPDH served as internal controls for miR-605 and FOXP1 mRNA levels, respectively. The $2^{-\Delta\Delta Cq}$ method was used to calculate the relative gene expression.²²

3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) assay

Transfected cells were harvested after 24 h of incubation and inoculated into 96-well plates with a density of 2,500 cells/well. Cell proliferative potential was evaluated by art ATT assay at 0, 24, 48 and 72 h after inoculation. Briefly, 20 d or MTT solution (5 mg/mL, Sigma-Aldrich, St. Louis, Q USA) was added into each well prior to incoloute at 37 V with 5% CO₂ for 4 h. Subsequently, the alture maximum was replaced with 100 μl of dimethyl sulfaxide DM (3). And the formazan was solubilized, the asorbance at 490 nm was detected using a microplate each (Model 5). Bio-Rad Laboratories, Inc., Hercules, CA, USA

Cell apoptosic assa

Annexin V-c rescer isothiog anate (FITC) apoptosis iego, CA, USA) was used detection At (Bio gend, of apoptotic cells. In detail, transto dete the per ere collected by trypsinization, washed with fected cell ice-cold phost ate buffer saline (PBS) (both from Gibco, Thermo Fisher Scientific, Inc., Waltham, MA, USA) and then suspended in 100 µl of binding buffer. A volume of 5 μl of Annexin V-FITC and 5 μl of propidium iodide were added to the cell suspension and the cells were further incubated at room temperature for 15 min in darkness. Finally, a flow cytometer (FACScanTM, BD Biosciences, Franklin Lakes, NJ, USA) was utilized to determine the cell apoptotic rate.

Transwell migration and invasion assays

Transwell inserts (Costar, Cambridge, MA, USA) precoated with Matrigel (BD Biosciences, Franklin Lakes, NJ, USA) on the upper surface were used for invasion assay or without Matrigel for migration assay. Following transfection for 48 h, cells were harvested and suspended in FBS-free DMEM. In total, 5×10⁴ cells were plated into the upper compartments of the Transwell inserts and 200 µl of DMEM supplemented with 20% FBS was added in the lower compartments as a chemoattractant. After 24 h ubation, the cells remaining in upper comparatents we wiped using a cotton swab. Cells on the underside f the inserts were fixed with 4% araform dehyde stained with 0.05% crystal viol, washed with 25 and air-dried. The number of Us at had passed through the s count under in inverted microscope membrane y (Olympu 13; Olympu orporation, Tokyo, Japan) and photograph

fumor xmograft assay

speriments were approved by the Ethics ll animal w Comittee of Liyuan Hospital of Tongji Medical College of Huazhong University of Science and Technology, and were conducted in accordance with the Animal Protection Law of the People's Republic of China-2009 for experimental animals. Animals were maintained following the guidelines for use and care of laboratory animals. 4-6-week-old BALB/c nude mice were purchased from Shanghai Laboratory Animal Center (Chinese Academy of Sciences, Shanghai, China). A total of 2×10⁶ cells transfected with miR-605 mimics or miR-NC were subcutaneously injected into the rear flank of nude mice. The tumor width and length were measured every four days and the tumor volume was analyzed using the formula V (mm3) = width2 $(mm2) \times length (mm)/2$. One month later, all nude mice were executed, and the xenografts were dissected out and weighed.

Target prediction and luciferase reporter assay

The putative targets of miR-605 were predicted using three miRNA target prediction software, including miRDB (http://www.mirdb.org/), miRanda (http://www.microrna.org), and TargetScan (http://www.targetscan.org/).

OncoTargets and Therapy 2019:12 submit your manuscript | www.dovepress.com
DovePress

The 3'-UTR fragments of FOXP1 containing the wildtype miR-605 binding sequences and mutant FOXP1 3'-UTR were amplified by GenePharma Co. Ltd., and cloned into the pMIR-REPORT vector (Promega, Madison, WI, USA). These reporter plasmids were designated as wildtype pMIR-FOXP1-3'-UTR and mutant pMIR-FOXP1-3'-UTR, respectively. Cells were inoculated into 24-well plates one day prior to transfection, miR-605 mimics or miR-NC, in combination with wild-type pMIR-FOXP1-3'-UTR or mutant pMIR-FOXP1-3'-UTR, was introduced into cells using LipofectamineTM 2000, in accordance with the manufacturer's instructions. At 48 h after treatment, transfected cells were harvested and luciferase activity was detected using a Dual-Luciferase Reporter Assay system (Promega, Madison, WI, USA). Firefly luciferase activity was normalized against Renilla luciferase activity.

Western blot analysis

Cells or homogenized tissues were lysed using radioimmunoprecipitation assay lysis buffer (Beyotime Institute of Biotechnology, Shanghai, China) containing a protease inhibitor cocktail (Sigma-Aldrich, St. Louis, MO, USA). The concentration of total protein was quantified using a BCA Protein Assay Reagent kit (Pierce, Thermo Fisher Scientific, Inc., Waltham, MA, USA) according to the manufacturer protocol. Equal amounts of total protein were contacted using a 10% SDS-PAGE gel and then transferred onto PVDF membranes (EMD Millipore, Biller, MA, MA).

Subsequent to blocking at room to peral with 5% fat-free dried milk diluted in Touffered sa e with 0.1% Tween-20 (TBST) for 5n, the membranes were incubated with the primary intibodies over ight at 4 °C. The primary antibodies ed in this study were as follows: rabbit anti-human FCP1 abody (1:1,000, cat. no. bbit \ -humar GAPDH antibody ab196978) and ab181 3 both from Abcam, no. (1:1,000, ca)condish peroxidase-conjugated goat Cambridge (K). H anti-rabbit sectory antibody (cat. no. ab205718, Abcam, Cambridge, UK) s used at a dilution of 1:5,000 for 2 h at room temperature and the protein signals were detected using a Pierce ECL Western Blotting Substrate (Pierce, Thermo Fisher Scientific, Inc., Waltham, MA, USA).

Statistical analysis

All results from at least three independent experiments were shown as mean \pm standard deviation and analyzed using SPSS software, v. 19.0 for Windows (IBM Corp.

Armonk, NY, USA). Student's Two-tailed *t*-test was used for comparison of two treatment groups. One-way analysis of variance followed by the Bonferroni post hoc test was performed to evaluate the differences between multiple groups. Chi-square test was employed to determine the correlation of expression of miR-605 and clinicopathological characteristics in NSCLC patients. The association between FOXP1 mRNA and miR-605 expression levels was analyzed by Spearman's correlation analysis. *P*<0.05 was considered to indicate a statistically significant difference.

Results

miR-605 expression is declared in NSCLC tissues and cell lines

To examine the expession tus of p-R-605 in NSCLC, RT-qPCR was formed to tect AR-605 expression in 45 pairs of ASC tissues and adjacent normal lung tissues. The results so wed that the expression level of 5 was notably lower in NSCLC tissues than that in adjeent normal ing tissues (Figure 1A, P<0.05). We next ed the relationship between miR-605 expression and clinico thole cal characteristics, to clarify the clinical of miR-605 in NSCLC patients. Chi-square test acates that decreased expression of miR-605 was significantly correlated with tumor size (P=0.026), TNM age (P=0.004), and distant metastasis (P=0.023), but not with the gender, age, histological tumor type and tumor differentiation (all P>0.05; Table 1). Furthermore, the data obtained from RT-qPCR analysis revealed that miR-605 was frequently downregulated in all four NSCLC cell lines (H460, SK-MES-1, H522, and H1299) relative to its expression in a non-tumorigenic bronchial epithelium cell line BEAS-2B (Figure 1B, P<0.05). Collectively, these observations strongly implied that a change in miR-605 expression might be related to the progression of NSCLC.

miR-605 inhibits the malignant phenotype of NSCLC in vitro

H460 and H522 cell lines showed relatively lower miR-605 expression among the four NSCLC cell lines and hence, these two NSCLC cell lines were selected for further functional assays. To illustrate the role of miR-605 in the aggressiveness of NSCLC cells, H460 and H522 cells were transfected with miR-605 mimics in




Figure 1 miR-605 is downregulated in NSCLC tissues and cell lines. (A) The expression of miR-605 in 45 pairs of NSCLC tissues and adjacent in the pall lung tissues was detected using RT-qPCR. *P<0.05 vs normal lung tissues. (B) RT-qPCR was performed to determine miR-605 expression in a total of the NSCLC cell lie (H460, SK-MES-I, H522 and H1299). Non-tumorigenic bronchial epithelium cell line BEAS-2B was used as a control. *P<0.05 vs BEAS-2B.

Table 1 Associations between miR-605 expression and clinic-pathological characteristics in NSCLC patients

Characteristics	miR-605		
	Low	High	P
Gender			0.672
Female	15	13	
Male	8	9	
Age (years)			
<60	6	12	
≥60	17	10	
Tumor size (cm)			0.026
<3	7	14	
≥3	16		
Histological tumor type			0.420
Adenocarcinoma	13	15	
Squamous cell carcinoma	10	7	
Tumor differentiation			0.399
1-11	9	6	
III-IV	14	16	
TNM sta	V		0.004*
1-11	8	17	
III+IV	15	5	
Distant meta sis			0.023*
Negative	9	16	
Positive	14	6	

Note: **P*<0.05.

order to increase endogenous miR-605 expression (Figure 2A, P<0.05). miR-NC served as a control for miR-605. MTT assay was performed to detect cellular proliferation, and it was demonstrated that the proliferative ability of H460 and H522 cells transfected with miR-605 mimics

was significantly in comparison to cells transure 2B < 0.05). In addition, the X-NC effect of ulated mik 05 in the apoptosis of NSCLC ed via cell apoptosis assay. As expected, cells was determ miR-605 ex ression enhanced the percentages of poptotic cells in H460 and H522 cell lines (Figure 2C, (<0.05). Transwell migration and invasion assays were</p> ther perfemed to explore whether miR-605 might migration and invasion of NSCLC cells. The showed that overexpression of miR-605 significantly decreased the migratory (Figure 2D, P<0.05) and invasive (Figure 2E, P<0.05) capacities of H460 and H522 cells compared to the miR-NC group. These results suggested that miR-605 might exert an inhibitory role in NSCLC cell growth and metastasis, in vitro.

FOXPI is a direct target gene of miR-605 in NSCLC cells

To elucidate the downstream regulatory mechanism of action of miR-605 in NSCLC cells, bioinformatics analysis was performed to search for the putative target of miR-605. Based on the results, *FOXP1* (Figure 3A) ignited our interest since this gene plays crucial roles in the progression and development of NSCLC.²³ Luciferase reporter assay was performed to determine whether miR-605 was able to directly target the 3'-UTR of FOXP1 in NSCLC cells. Restoring the expression of miR-605 significantly decreased the luciferase activity of wild-type pMIR-FOXP1-3'-UTR in both H460 and H522 cells (*P*<0.05), whereas the inhibitory effect was abrogated when the binding sequences of miR-605 in the 3'-UTR of FOXP1 were mutated (Figure 3B). To further confirm whether FOXP1 is a direct target of miR-605, we detected its

OncoTargets and Therapy 2019:12 submit your manuscript | www.dovepress.com DovePress

Zhou and Li Dovepress





Figure 2 miR-605 exerts tumor-supprying roles in No.C cells. (A) Quantitation of the expression of miR-605 through RT-qPCR in H460 and H522 cells after transfection with miR-605 mimics or miR-NC. *P<0.05 vs miR-VC. (B) MTT assay showed the proliferative ability of H460 and H522 cells transfected with miR-605 mimics or miR-NC. *P<0.05 vs miR-NC. (b) The percentage of apoptody H460 and H522 cells with indicated treatments was evaluated by cell apoptosis assay. *P<0.05 vs miR-NC. (D, E) Representative images a quantitation of the expression of miR-NC. *P<0.05 vs miR-NC. *P<0.05 v

expression is ASCLC issues are examined its relationship with miR-60 RT μ CR. Sysis demonstrated that both FOXP1 mRNA regure 3C, P<0.05) and protein (Figure 3D, P<0.05) levels were stably elevated in NSCLC tissues compared to that in adjacent normal lung tissues. Furthermore, an inverse association between miR-605 and FOXP1 mRNA levels was identified in NSCLC tissues (Figure 3E; r= -0.5480, P<0.0001). Moreover, decreased FOXP1 mRNA (Figure 3F, P<0.05) and protein (Figure 3G, P<0.05) levels were observed in miR-605-overexpressing H460 and H522 cells. Therefore, we drew a conclusion that FOXP1 is the direct target gene of miR-605 in NSCLC cells.

FOXPI inhibition shows effects similar to miR-605 overexpression in NSCLC cells

To determine the role of FOXP1 in the malignant progression of NSCLC, small interfering RNA targeting FOXP1 expression (si-FOXP1) and negative control siRNA (si-NC) were transfected into H460 and H522 cells. The protein level of FOXP1 was notably downregulated in H460 and H522 cells after si-FOXP1 transfection, as measured by western blot analysis (Figure 4A, P<0.05). MTT and cell apoptosis assays revealed that knockdown of FOXP1 restricted proliferation (Figure 4B, P<0.05) and promoted apoptosis (Figure 4C,



Compa on of sequences of miR-605 with wild-type or mutant putative binding sites in the 3'-UTR Figure 3 FOXPI is a direct target gene of miR-605 in NSQ 605 directly targets the 3'-UTR of FOXPI. Luciferase activity was detected in H460 and of FOXPI gene. (B) Luciferase reporter assay was empl d to dete ne that m H522 cells co-transfected with miR-605 mimics or m MIR-F XPI-3'-UTR or mutant pMIR-FOXPI-3'-UTR. *P<0.05 vs miR-NC. (**C, D**) The FOXPI mRNA and protein levels in NSCLC tissues and ung tissues—ere detected via RT-qPCR and western blot analysis, respectively. *P<0.05 vs normal lung iacei orrelation between miR-605 and FOXPI mRNA levels in NSCLC tissues. r=-0.5480, P<0.0001. (**F, G**) RTtissues. (E) Spearman's correlation analysis sh ed an inve NA and protein levels of FOXP1 in H460 and H522 cells transfected with miR-605 mimics or miR-NC. qPCR and western blot analysis was adop measure the *P<0.05 vs miR-NC.

P<0.05) of H460 and Z 322 cells compared Z cells transfected with si-NC. Further tore, the migration (Figure 4D, P<0.05) and invasion (Figure 4D, Z<0.05) of 1460 and H522 cells was suppressed by FG XP1 kinckly wn. These results indicated that FC XP1 siles ling exerted an impact in NSCLC cells similar to the caused by miR-605 overexpression, further suggesting the FOXP1 is a direct target of miR-605.

FOXPI restoration abrogates the antitumor effects of miR-605 in NSCLC cells

A series of rescue experiments were further performed to verify whether FOXP1 contributes to miR-605-mediated tumor-suppressing activity in NSCLC cells. To this end, miR-605-overexpressing H460 and H522

cells were further transfected with FOXP1 overexpression vector pCMV-FOXP1 or pCMV empty plasmid. Transfection of pCMV-FOXP1 partially restored the decreased FOXP1 protein level in miR-605 mimicstransfected H460 and H522 cells (Figure 5A, P<0.05). As expected, the restored FOXP1 expression reversed the suppressive effects of miR-605 overexpression in H460 and H522 cells, with respect to proliferation (Figure 5B, P<0.05), apoptosis (Figure 5C, P<0.05), migration (Figure 5D, P<0.05) and invasion (Figure 5E, P<0.05), in vitro. Overall, these results clearly demonstrated that miR-605 conferred its antitumor effect in NSCLC cells by directly targeting and downregulating FOXP1 and the downregulation of FOXP1 by miR-605 was essential for the tumor suppressive roles of miR-605 in NSCLC cells.

OncoTargets and Therapy 2019:12 submit your manuscript | www.dovepress.com DovePress

Zhou and Li

Dovepress




Figure 4 Inhibition of the PI is able to imitate the anticancer effects of miR-605 upregulation in NSCLC cells. (A) H460 and H522 cells were transfected with si-FOXPI or si-NC. After 72 h of transfection, ckdown of FOXPI was efficient in H460 and H522 cells, as demonstrated by western blot analysis. *P<0.05 vs si-NC. (B, C) MTT and cell apoptosis assays were conducted to exame the effects of FOXPI silencing on NSCLC cell proliferation and apoptosis, respectively. *P<0.05 vs si-NC. (D, E) The migratory and invasive capacities of H460 and H522 cells after si-FOXPI or si-NC transfection were evaluated through transwell migration and invasion assays. *P<0.05 vs si-NC.

Overexpression of miR-605 hinders tumor growth of NSCLC cells in vivo

Tumor xenograft assay was performed to assess the effect of miR-605 overexpression on the growth of NSCLC cells in vivo. H460 cells were transfected with miR-605 mimics

or miR-NC. Cells were collected after 24 h of transfection and subcutaneously injected into nude mice to generate transplanted tumors of BALB/c nude mice. The tumor volume was measured every four days. One month after implantation, the xenografts were dissected and the exact




Figure 5 Restoration of FOXPI expression reverses the tumor-suppressing effects of miR-605 in NSCLC cells. miR-605 mimics in combination with pCMV-FOXPI or pCMV was co-transfected into H460 and H522 cells. (A) Western blot analysis was performed at 72 h post-transfection to measure FOXPI protein expression. *P<0.05 vs miR-NC. **P<0.05 vs miR-605 mimics + pCMV. (B-E) The proliferation, apoptosis, migration and invasion of above mentioned cells was determined through MTT, cell apoptosis, transwell migration and invasion assays, respectively. *P<0.05 vs miR-NC. **P<0.05 vs miR-605 mimics + pCMV.

volume and weights were evaluated. The tumor volume (Figure 6A) and weights (Figure 6B, P<0.05) of the xenografts from mice injected with miR-605 mimics were significantly suppressed relative to those that received the

miR-NC. The tumor growth curve indicated an obvious suppression in the miR-605 mimics group compared to the miR-NC group (Figure 6C, *P*<0.05). Meanwhile, RT-qPCR analysis was carried out to detect the expression

Zhou and Li **Dove**press




Figure 6 miR-605 suppresses tumor growth of NSCLC cell umor xenografts were obtained from nude mice that were injected with miR-605 nografts in mix-605 mimics and miR-NC groups was detected. *P<0.05 vs miR-NC. (**C**) The tumor mimics or miR-NC transfected H460 cells. (B) The wa t of idth2 (mn length (mm)/2. Growth curve of tumor volumes was calculated. *P<0.05 vs miR-NC. (**D**) Expression volume was determined using the formula V (mm3) R. *P<0.05 vs r level of miR-605 in xenografts was detected by B NC. (E) FOXPI protein expression in the tumor xenografts was assessed by western blot analysis.

rafts. The data showed that the of miR-605 in the xend expression level of mi 605 is higher in the xenografts derived from the iR-60s spressip H460 cells (Figure 6D, P<0.05). significant decrease in oreov there gion in the miR-605 mimics group FOXP1 proin exp A the miR-NC group (Figure 6E). These compared to the observations den astrated that miR-605 inhibits the growth of NSCLC cols, in vivo.

Discussion

Recently, the changes in miRNA expression are currently a hot research area. 24,25 The dysregulation of miRNAs in NSCLC has been widely reported in accumulating studies.²⁶⁻²⁸ Aberrantly expressed miRNAs are closely correlated with the malignant progression of NSCLC and participate in the regulation of various biological behaviors. 11 Hence, in-depth studies of the effects of crucial miRNAs in NSCLC progression might provide a novel insight into their use as potential therapeutic targets for treating patients with this deadly disease. This study, for the first time, detected miR-605 expression in NSCLC, investigated the regulatory roles of this miRNA with respect to the aggressive behaviors of NSCLC and explored the possible underlying mechanisms.

miR-605 has been well-studied in multiple types of malignant tumors. For example, miR-605 is downregulated in melanoma tissues and cell lines. Restoring miR-605 expression decreased melanoma cell growth in vitro and in vivo. 19 Expression level of miR-605 was also lower in prostate cancer tissues and cell lines. The upregulation of miR-605 inhibited the proliferation and invasion of prostate cancer cells.²⁰ A study by Li et al revealed that

miR-605 expression was decreased in intrahepatic cholangiocarcinoma. Restoration of miR-605 expression restricted cell progression in vitro and in vivo.²¹ However, the expression pattern and specific roles of miR-605 in NSCLC remain to be elucidated. Herein, RT-qPCR analysis indicated that miR-605 was expressed at low levels in NSCLC tissues and cell lines. Low expression of miR-605 was observed to be correlated with tumor size, TNM stage and distant metastasis in NSCLC patients. Functionally, miR-605 overexpression was able to inhibit the proliferation, induce apoptosis and suppress metastasis of NSCLC cells in vitro, as well as decrease tumor growth in vivo. These findings suggest that miR-605 might be a potential diagnostic biomarker and therapeutic target for patients with the above specific cancer type.

Three human genes, including INPP4B in melanoma, ¹⁹ EN2 in prostate cancer, ²⁰ and PSMD10/ Gankyrin in intrahepatic cholangiocarcinoma,²¹ have been demonstrated to be direct targets of miR-605. Hence, we next attempted to investigate the underlying mechanisms by which miR-605 might affect the oncogenicity of NSCLC cells. First, FOXP1 was predicted to be a potential target of miR-605, by all three miRNA target prediction software. Second, miR-605 directly bind to the 3'-UTR of FOXP1 in NS cells, as demonstrated by luciferase remoter as Third, highly expressed FOXP1 in NS CC to inversely correlated with miR-605 pressi the mRNA and protein levels FOX vere notably downregulated in NSCLC cell upon miR- upregulation. Fifth, inhibition of FCAP1 bibited simular effects on miR-605 in NSCLC ells. Finally, OXP1 restoration partially attenuated the suppression phenotype driven by miR-605 upregulation in NSCLC cells. These results provided uner ivocal vidence support that miR-605 gressi ogression of NSCLC by suppress the directly targeting FOXP1 and that downregulation of R-605 was essential for miR-605-induced FOXP1 antitumor roll in NSCLC.

FOXP1 was arst identified by Shu et al,²⁹ and it was considered as a glutamine rich factor. FOXP1 is a member of the forkhead box transcription factor family.³⁰ It is a transcription inhibitor and has been reported to be dysregulated in multiple human cancers. 31-33 One previous study reported that FOXP1 was upregulated in NSCLC at both mRNA and protein levels.²³ High FOXP1 expression was significantly correlated with gender and histologic type in NSCLC patients. These patients with high FOXP1

expression had shorter five-year survival rate than patients with low FOXP1 expression.²³ Furthermore, Kaplan-Meier survival and cox regression analyses identified FOXP1 expression as an independent biomarker to predict the poor prognosis of patients with NSCLC.²³ In this study, we revealed that inhibition of FOXP1 suppressed NSCLC cell proliferation, promoted cell apoptosis, and decreased cell migration and invasion, in vitro. Notably, miR-605 directly targeted FOXP1, thereby inhibiting the malignant progression of NSCLC cells. Accordingly, targeting FOXP1 by restoring the expression of miR-605 might be an effective therapeutic approach for NSCL patients.

Conclusion

To our knowledge, s is the first stu confirm that the downregulation of R-66 is a common phenomenon in NSCLC tissy and certines an that this downregulation of miR-66 rignificantly related with the tumor size, TNM stage, and listant metastasis. In addition, increased expression can prohibit the progression of SCLC in vitro and in vivo by directly targeting findings might provide a new insight into CLC car hogenesis and miR-605 could be developed as a potential therapeutic target for this cancer type.

Abbreviation list

NSCLC, Non-small-cell lung cancer; RT-qPCR, Quantitative reverse transcription-quantitative polymerase chain reaction; miRNA, microRNA; DMEM, Dulbecco's modified Eagle's medium; FBS, Fetal bovine serum; miRNA, microRNA; miR-NC, negative control miRNA mimics; siRNA, Small interfering RNA; si-NC, negative siRNA; MTT, 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide; DMSO, dimethyl sulfoxide; FITC, Annexin V-fluorescein isothiocyanate; PBS, phosphate buffer saline; TBST, Tris-buffered saline with 0.1% Tween-20; 3'-UTR, 3'-Untranslated region.

Disclosure

The authors report no conflicts of interest in this work.

References

- 1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87-108. doi:10.3322/caac.21262
- 2. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359386. doi:10.1002/ijc.29210

submit your manuscript 3775 OncoTargets and Therapy 2019:12

Zhou and Li Dovepress

 Torre LA, Sauer AM, Chen MS Jr, Kagawa-Singer M, Jemal A, Siegel RL. Cancer statistics for Asian Americans, Native Hawaiians, and Pacific Islanders, 2016: converging incidence in males and females. CA Cancer J Clin. 2016;66(3):182–202. doi:10.3322/caac.21335

- Burdett S, Pignon JP, Tierney J, et al. Adjuvant chemotherapy for resected early-stage non-small cell lung cancer. *Cochrane Database* Syst Rev. 2015;(3):CD011430.
- Thomas A, Liu SV, Subramaniam DS, Giaccone G. Refining the treatment of NSCLC according to histological and molecular subtypes. *Nat Rev Clin Oncol*. 2015;12(9):511–526. doi:10.1038/ nrclinonc.2015.90
- Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6(11):857–866. doi:10.1038/nrc1997
- Behm-Ansmant I, Rehwinkel J, Izaurralde E. MicroRNAs silence gene expression by repressing protein expression and/or by promoting mRNA decay. Cold Spring Harb Symp Quant Biol. 2006;71:523–530. doi:10.1101/sqb.2006.71.013
- 8. Dias F, Morais M, Teixeira AL, Medeiros R. Involving the microRNA targetome in esophageal-cancer development and behavior. *Cancers*. 2018;10(10). doi:10.3390/cancers10110400
- Zhu Z, Zhang X, Wang G, Zheng H. Role of MicroRNAs in hepatocellular carcinoma. *Hepat Mon.* 2014;14(8):e18672. doi:10.5812/ hepatmon.18672
- Yu H, Guan Z, Cuk K, Brenner H, Zhang Y. Circulating microRNA biomarkers for lung cancer detection in Western populations. *Cancer Med.* 2018;7:4849–4862. doi:10.1002/cam4.2018.7.issue-10
- Han Y, Li H. miRNAs as biomarkers and for the early detection of non-small cell lung cancer (NSCLC). *J Thorac Dis.* 2018;10 (5):3119–3131. doi:10.21037/jtd.2018.05.32
- Chen W, Huang Y, Zhang S, et al. MicroRNA-212 suppresses non-small lung cancer invasion and migration by regulating ubiquitin-specific protease-9. *J Cell Biochem*. 2019;120(4):6489.
- Song Q, Ji Q, Xiao J, et al. miR-409 inhibits human non-small-cellung cancer progression by directly targeting SPINL 101 Then Nucleic Acids. 2018;13:154–163. doi:10.1016/j.omtp. 18.00. 20
- 14. He X, Chen SY, Yang Z, et al. miR-4317 suppress non-small cell lung cancer (NSCLC) by targeting fibroblast ground factor and cyclin D2 (CCND2). *J Exp Clinl Can Res.* 21, 37(1):230. doi:10.1186/s13046-018-0882-4
- 15. Li S, Zeng X, Ma R, Wang L. MicroPour Lt promotes the coliferation, migration and invasion of none mall certain cancer Assay cells by regulating autophagy activity via AM V/ULK1 signaling pathway. Exp Ther Med 2018;16(3):2038–201. doi:10.3892/etm.2018.6370
- 16. Jin X, Yu Y, Zon Q, et al. MicroRNA-105 promotes epithelial-mesenchymal train of a nonsmall mg cancer cells through upregulating Mclarific Mg 2019; 10(4):5880–5888.
- 17. Li Y, Cui X, Y, Zhao T, Li S. are alated expression of miR-421 is associated with poor ognosis in non-small-cell lung cancer. *Cancer Manag Res.* 918;17, 227. doi:10.2147/CMAR.S167432
- Boeri M, Paste J U, Sozzi G. Role of microRNAs in lung cancer: microRNA sign. ses in cancer prognosis. Cancer J. 2012;18 (3):268–274. doi:10. 07/PPO.0b013e318258b743

 Chen L, Cao Y, Rong D, Wang Y, Cao Y. MicroRNA-605 functions as a tumor suppressor by targeting INPP4B in melanoma. *Oncol Rep.* 2017;38(2):1276–1286. doi:10.3892/or.2017.5740

- Zhou YJ, Yang HQ, Xia W, et al. Down-regulation of miR-605 promotes the proliferation and invasion of prostate cancer cells by up-regulating EN2. *Life Sci.* 2017;190:7–14. doi:10.1016/j. lfs.2017.09.028
- 21. Li J, Tian F, Li D, et al. MiR-605 represses PSMD10/Gankyrin and inhibits intrahepatic cholangiocarcinoma cell progression. FEBS Lett. 2014;588(18):3491–3500. doi:10.1016/j. febslet.2014.08.008
- Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. *Methods*. 2001;25(4):402–408. doi:10.1006/meth.2001.1262
- 23. Feng J, Zhang X, Zhu H, Wang X, Ni S, Huar J, High expression of FoxP1 is associated with improved arvival patients with non-small cell lung cancer. *April Clin Patro* 2012;138 (2):230–235. doi:10.1309/AJCPDHQL VJZ01YG
- 24. Song CJ, Chen H, Chen LZ, Ry, M, Gue, Ding QN, the potential of microRNAs as human protein cancer biot takers: meta-analysis of related studies. *J ell Biot m.* 20. 20(3):2763–2786. doi:10.1002/jcb.26445
- 25. Hajizamani S, Shabahani S, Jaki N. MicroRNAs as prognostic biore ker and relap indication leukemia. *Clin Transl Oncol*. 2017 (c. 51–960. doi: 1. 16/s12094-017-1638-x
- 26. Lu J, Zhan J, Feng Luo J, Fan S. MicroRNAs associated with therapy of non-small U lung cancer. *Int J Biol Sci.* 2018;14 (4) 3-5-3. doi:10.7150/j. 22243
- 27. V din A, Chakraborty S. Kole of miRNAs in lung cancer. J Cell vsiol. 2018. di 10.1002/jcp.26607
- 28. 2 au Q, Huang S, Zhang F, et al. MicroRNAs: A novel potential bit orker for dignosis and therapy in patients with non-small cell lung c. *A Prolif.* 2017;50(6). doi:10.1111/cpr.12368
- thu W, Yang H, Zhang L, Lu MM, Morrisey EE. Characterization of ubfamily of winged-helix/forkhead (Fox) genes that are expressed in the lung and act as transcriptional repressors. *J Biol Chem.* 2001;276(29):27488–27497. doi:10.1074/jbc.M100636200
- O. Hu Z, Zhu L, Gao J, et al. Expression of FOXP1 in epithelial ovarian cancer (EOC) and its correlation with chemotherapy resistance and prognosis. *Tumor Biol.* 2015;36(9):7269–7275. doi:10.1007/s13277-015-3383-5
- 31. Xiao J, He B, Zou Y, et al. Prognostic value of decreased FOXP1 protein expression in various tumors: a systematic review and meta-analysis. Sci Rep. 2016;6:30437. doi:10.1038/srep30437
- 32. Mizunuma M, Yokoyama Y, Futagami M, Horie K, Watanabe J, Mizunuma H. FOXP1 forkhead transcription factor is associated with the pathogenesis of endometrial cancer. *Heliyon*. 2016;2(5): e00116. doi:10.1016/j.heliyon.2016.e00116
- Choi EJ, Seo EJ, Kim DK, et al. FOXP1 functions as an oncogene in promoting cancer stem cell-like characteristics in ovarian cancer cells. *Oncotarget*. 2016;7(3):3506–3519. doi:10.18632/oncotarget. 6510



OncoTargets and Therapy

Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic

agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

 $\textbf{Submit your manuscript here:} \ \texttt{https://www.dovepress.com/oncotargets-and-therapy-journal}$

3777 submit your manuscript | wo